Barclays analyst Jack Meehan raised his price target for Bio-Rad Laboratories to $340 saying the company’s Q4 results “hit all the important marks.” The analyst views the initial 2019 guidance as better than expected and continues to believe that Bio-Rad has “substantial long-term opportunity ahead.” He also thinks the stock’s current valuation is “compelling” and reiterates an Overweight rating on the name.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.